



King's Research Portal

DOI:

[10.1016/j.jpsychores.2017.09.006](https://doi.org/10.1016/j.jpsychores.2017.09.006)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Ilzarbe, L., Fàbrega, M., Quintero, R., Bastidas, A., Pintor, L., García-Campayo, J., Gomollón, F., & Ilzarbe, D. (2017). Inflammatory Bowel Disease and Eating Disorders: A systematized review of comorbidity. *Journal of Psychosomatic Research*. <https://doi.org/10.1016/j.jpsychores.2017.09.006>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal


Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Inflammatory Bowel Disease and Eating Disorders: A systematized review of comorbidity

L. Ilzarbe, M. Fàbrega, R. Quintero, A. Bastidas, L. Pintor, J. García-Campayo, F. Gomollón, D. Ilzarbe



PII: S0022-3999(17)30785-7
DOI: doi: [10.1016/j.jpsychores.2017.09.006](https://doi.org/10.1016/j.jpsychores.2017.09.006)
Reference: PSR 9405
To appear in: *Journal of Psychosomatic Research*
Received date: 21 June 2017
Revised date: 27 August 2017
Accepted date: 13 September 2017

Please cite this article as: L. Ilzarbe, M. Fàbrega, R. Quintero, A. Bastidas, L. Pintor, J. García-Campayo, F. Gomollón, D. Ilzarbe , Inflammatory Bowel Disease and Eating Disorders: A systematized review of comorbidity. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. *PSR*(2017), doi: [10.1016/j.jpsychores.2017.09.006](https://doi.org/10.1016/j.jpsychores.2017.09.006)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

INFLAMMATORY BOWEL DISEASE AND EATING DISORDERS: A SYSTEMATIZED REVIEW OF COMORBIDITY

Ilzarbe L¹, Fàbrega M², Quintero R³, Bastidas A⁴, Pintor L³, García-Campayo J^{1,5,6,7}, Gomollón F^{1,6,8,9}, Ilzarbe D^{10,11}.

1. Faculty of Medicine, Universidad de Zaragoza, Zaragoza, Spain.
2. Department of Child and Adolescent Psychiatry, Imperial College London, London, United Kingdom.
3. Psychosomatic and Liason Psychiatry Unit, Department of Psychiatry and Psychology, Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.
4. Acute Inpatient Unit, Department of Psychiatry and Psychology, Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.
5. Department of Psychiatry, Hospital Universitario Miguel Servet, Zaragoza, Spain.
6. Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.
7. Network for Prevention and Health Promotion in Primary Care (RedIAPP), Madrid, Spain
8. Inflammatory Bowel Disease Unit, Department of gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
9. Centro de Investigación Biomédica en Red, Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
10. Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, United Kingdom.
11. Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.

EMAIL OF AUTHORS

Lidia Ilzarbe: lidilsim@gmail.com

Marina Fàbrega: m.fabrega-ribera@imperial.ac.uk

Rafael Quintero: rquintero@clinic.ub.es

Ana Bastidas: bastidas@clinic.cat

Luis Pintor: lpintor@clinic.ub.es

Javier García-Campayo: jgarcamp@gmail.com

Fernando Gomollón: fgomollon@gmail.com

Daniel Ilzarbe: daniel.ilzarbe_simorte@kcl.ac.uk

ADDRESS FOR CORRESPONDENCE

Daniel Ilzarbe Simorte

Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and
Neurosciences, King's College London (PO85), 16 De Crespigny Park

London, United Kingdom, SE5 8AF

Phone: 020 7848 5312

Fax: 020 7708 5800

daniel.ilzarbe_simorte@kcl.ac.uk

ABSTRACT

Objective. Research has shown that there is an association between Inflammatory Bowel Disease, anxiety and mood disorders, however little is known about their association with Eating Disorders. In this paper we will present a case of a young female with a comorbid diagnosis of Inflammatory Bowel Disease and Eating Disorder, and then discuss the results from a systematic review of the literature, describing published cases of patients with the same condition.

Methods. A systematized review of the literature was conducted according to MOOSE guidelines. A computerized literature search of MEDLINE, PsycINFO and EMBASE, and a manual search through reference lists of selected original articles were performed to identify all published case-reports, case series and studies of Inflammatory Bowel Disease and Eating Disorders.

Results. Fourteen articles were included, encompassing 219 cases, including ours. The vast majority were females ranging from 10 to 44 years old. Anorexia Nervosa (n=156) and Crohn's Disease (n=129) was the most frequent combination (n=90) reported in the literature. These cases present a poor prognosis because of corticoid refusal, medication abandon and/or deliberate exacerbation of IBD symptoms, in the context of trying to lose weight.

Conclusion. Recent evidence suggests there is a possible association between Inflammatory Bowel Disease and Eating Disorders, although the mechanisms involved in its ethiopathogenesis are still unknown. To be aware of this association is important because a delayed diagnosis of this comorbidity may lead to worse prognosis. Further research and a multidisciplinary approach could facilitate earlier diagnosis and provide therapeutic interventions

KEY WORDS.

Anorexia Nervosa, Bulimia Nervosa, Crohn's Disease, Eating Disorders, Inflammatory Bowel Disease, Ulcerative Colitis.

MANUSCRIPT

INTRODUCTION

Inflammatory Bowel Disease (IBD) is a group of conditions/disorders characterized by chronic inflammation of the gastrointestinal tract and episodes of relapses and remissions; especially in genetically susceptible individuals exposed to environmental risk factors^{1,2}. IBD comprises Crohn's Disease (CD), Ulcerative Colitis (UC), microscopic colitis, indeterminate colitis and pouchitis³. The prevalence of IBD may be increasing as a result of the low mortality, the earlier diagnoses and the longer duration of disease¹. The registered prevalence of CD varies from 0.6 to 322 per 100,000 in Europe, and from 4.9 to 505 per 100,000 in case of UC². Most studies showed a peak incidence in the second to fourth decade, with the highest incidence amongst 20 to 29 year old^{1,2}. There are not great differences between males and females^{1,2}.

The association between IBD and some mental disorders, especially anxiety and mood disorders, has been extensively studied⁴⁻⁶. According to the meta-analysis by Neuendorf et al.⁶, the prevalence of anxiety and depressive disorders in IBD is 21% and 15% respectively. These rates increase up to 35% for anxiety symptoms and 22% for depressive symptomatology. However, other mental disorders have received sparse attention in literature. Especially, and despite the potential overlap in symptoms, the relationship between eating disorders (ED) and IBD has not been widely studied.

Anorexia Nervosa (AN) and Bulimia Nervosa (BN) have been the main diseases classically established as ED⁷. Nevertheless, eating disorder not otherwise specified (EDNOS), which includes partial syndromes of AN and BN, has been the most commonly diagnosed⁸ till the recent publication of Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5)⁹. The point prevalence of EDNOS in a nation-wide community sample of young females was 2.4%⁸. In the case of AN and BN, the lifetime prevalence amongst women range from 0 to 0.9% and from 0.9 to 1.5% respectively⁸. AN has an overall incidence rate of 4.2-8.1 new cases

per 100,000 persons per year¹⁰. In addition, AN presents the highest rate of mortality amongst all psychiatric illnesses, with a Crude Mortality Rate of 5.1 deaths per 1000 person-years⁸.

There are some groups who have studied the role of diet in IBD¹¹⁻¹³. It has been reported that patients with IBD have strong beliefs about some food triggering IBD symptoms¹¹, which frequently drives them to avoid specific nutrients and/or reduce global intake. This may exacerbate malnutrition, and moreover it also may have an impact on their social life, as it usually involves events that include eating and drinking¹¹. Both, malnutrition and social isolation have been related with a significant reduction of quality of life in this population¹². In addition, there are common features in both ED and IBD (see table 1) which may lead to misdiagnosis. It has been reported mainly between IBD and AN¹⁴⁻²¹ due to the restrictive pattern¹³, body mass index (BMI) reduction, predominance of females and similar age of onset^{2,22,23}. Apart from the overlapping symptomatology, both conditions can also coexist as described in the case below, making differential diagnosis more difficult (see table I).

Table I. Similarities and differences between the clinical presentation of inflammatory bowel diseases and eating disorders.

		IBD	ED
Epidemiology	Ratio female:male	No differences ² CD: 0.34:1 to 1.65:1 ² UC: 0.51:1 to 1.58:1 ²	Higher in females ²² AN or BN: 5:1 to 10:1 ²²
	Age of highest incidence	CD or UC: 20-29 y/o ²	AN: 15-19 y/o ²³ BN: 20-24 y/o ²³
Common signs & symptoms	Diarrhoea	Due to inflammation	It could be related to laxative abuse
	Nausea and vomiting	Due to inflammation	It could be self-induced
	Reduced appetite	Secondary to abdominal pain and cramping, as well as inflammation	It can be present in AN
	Weight loss and malnourished (dehydration; anaemia; fatigue; amenorrhea in women)	Due to malabsorption	Due to reduced food intake
	Postprandial symptoms	Bloating Abdominal pain	Feeling of fullness, meteorism or flatulence Post-meal pains of the epigastrium
	Constipation	Due to inflammation (can lead to bowel obstruction)	Due to low food intake
	Differential signs and symptoms	Fever Blood in stool Fistula Tenesmus Fear of abdominal discomfort from eating food	Body image distortion Fear to gain weight
Case reported in the literature about misdiagnosis and/or differential diagnosis between IBD and ED		<u>Final diagnosis of IBD:</u> Gryboski et al. 1968 ¹⁴ Metcalf-Gibson et al. 1978 ¹⁵ Hershman et al. 1985 ¹⁶ Jenkins et al. 1988 ¹⁷ Andant et al. 1999 ¹⁸ Blanchet et al. 2002 ¹⁹ Markella et al. 2010 ²⁰	<u>Final diagnosis of ED:</u> Tylec et al. 2014 ²¹

AN = Anorexia Nervosa; BN = Bulimia Nervosa; CD = Crohn's Disease; ED = Eating Disorder; IBD = Inflammatory Bowel Disease; UC = Ulcerative Colitis.

There is a paucity of research looking at eating attitudes and behaviours in diet-related chronic health conditions²⁴ and autoimmune diseases such as IBD²⁵. Satherley et al.¹³ have recently reported higher prevalence of disordered eating symptoms in participants with IBD relative to healthy controls. Nevertheless, to our knowledge there is no previous review focusing on subjects with IBD fulfilling criteria for a diagnosis of an eating disorder. Thus, we present a case of a young female with a comorbid diagnosis of IBD and ED, and a systematized review of published cases of patients with the same condition.

Case report

A 20-year-old Caucasian woman, diagnosed with pancolonic and ileal CD at age 17, was admitted to the gastroenterology ward for autologous hematopoietic stem cell transplantation. She was corticoddependent, intolerant to infliximab and required enteral nutrition at admission. She had been under exclusive enteral nutrition for 8 months. She had also history of Primary Sclerosing Cholangitis (diagnosed the previous year). She reported irregular menstruation since the age of 14 and six months of amenorrhea before admission in relation with weight loss (from 60 to 47.5 kg in the previous year; height=1.70 metres; BMI=16.4). She lived with her parents and her 24-year-old brother. She had abandoned her studies due to her health condition.

Once admitted, the patient was referred to the liaison psychiatry unit for mood lability. She presented fluctuating low mood with loss of interest in her self-care and anxiety symptoms related to her condition (i.e. unmanageable fear of leaving home due to difficult accessibility to bathrooms). At the age of 19 she had been diagnosed with adjustment disorder and started treatment with paroxetine 20 mg/day and alprazolam 0.25 mg/day.

During her admission, she frequently refused to eat due to early satiety, abdominal pain and nausea, despite the gastroenterologist's recommendation of oral intake. In addition, she also hid prescribed medication and did not take it. Since the age of 14 she also reported a selective pattern of eating, progressive restriction of food intake, and feeling more comfortable using enteral nutrition. She did not describe body image disturbance or fear of gaining weight. Considering her BMI, the amenorrhea and the restrictive diet she was finally diagnosed with EDNOS.

METHODS

This systematized review was conducted according to the guidelines for Meta-Analyses and Systematic Reviews of Observational Studies (MOOSE)²⁶.

A computerized literature search of MEDLINE, PsycINFO and EMBASE was performed up to the 22nd of December 2016. Search strategy: "inflammatory bowel disease" OR "crohn's

disease" OR "ulcerative colitis" OR "microscopic colitis" OR "indeterminate colitis" OR "pouchitis" AND "eating disorder" OR "anorexia nervosa" OR "bulimia nervosa".

The reference lists of the identified original articles and case reports were also searched manually for additional records. Studies were assessed by first author (L.I.), and when in doubt, the final decision was made in consultation with a second author. Some authors were contacted to obtain further information. No limitations were placed on language, publication date and publication status.

The following inclusion criteria were used: (I) any data reported about patients with a comorbid diagnosis of IBD and AN, BN or EDNOS. The exclusion criteria were: (I) cases reported with misdiagnosed IBD or ED, or uncertain diagnosis; (II) reviews and published conference abstracts. Case reports and case series were included given the limited number of published epidemiological studies addressing this comorbidity. Publications with cases reporting additional comorbidities were not excluded.

Data were extracted from eligible articles according to the inclusion criteria in a pre-specified Microsoft Excel spreadsheet. The following information was collected: (I) demographic characteristics (including age, gender, number of patients and country of origin); (II) clinical characteristics (including type of IBD, age of diagnosis of IBD, type of ED, age of diagnosis of ED, first diagnosis, initial symptoms and other comorbidities) and; (III) treatment (including drugs and procedures).

RESULTS

The search strategy identified 495 records, after removing 80 duplicates. 461 were excluded at first screening based on titles and abstracts, leaving 34 articles for full text review. Of them, we included 14 articles, excluding 20 articles for the reasons listed in Figure I. Amongst the 14 articles, there were two retrospective cohort studies^{27,28}, six case reports²⁹⁻³⁴, and six case series^{19,35-39} (Table II).

Figure 1. Flowchart of literature search of comorbid eating disorders in inflammatory bowel disease.




Table II. Cases reported in the literature with inflammatory bowel disease and eating disorder comorbidity.


Author, Year	Country	Type of study	N	Sex	Age	ED	IBD	Other comorbidities	Cortico-therapy	ED treatment	Psycho-social and environmental factors reported
Sreenivasan ³⁵ , 1984	Canada	Case report	1	F	17	AN	UC		Yes	NS	
Anonymous ²⁹ , 1985	USA	Case report	1	M	18	EDNOS	CD	Mitral and aortic valves prolapse	Yes	Admission to psychiatric unit, and weekly psychotherapy sessions	Overweight in childhood, disturbance of family relationships
Meadows & Treasure ³⁶ , 1989	Australia	Case report	1	F	23	BN	CD		Yes	Psychological treatment	
			1	F	17	BN ^a	CD		Yes	NS	
Mallet & Murch ³⁷ , 1990	UK	Case report	1	M	14	AN	UC	Glucose 6-phosphate dehydrogenase, early puberty	Yes	Outpatient psychotherapy, dietary regime (and family therapy)	Teased at school for overweight, disturbance of family relationships
			1	F	13	AN	CD		Yes	Admission to psychiatric unit, behavioural regime and dietary regime	Teased at school for overweight
Gryboski ³⁸ , 1993	USA	Case report	1	F	14	BN ^a	UC	Lactose intolerance	No	NS	
			1	F	17	BN ^a	CD	Lactose intolerance, obesity	Yes	Outpatient psychotherapy	Best friend had BN
			1	F	14	EDNOS	UC	Lactose intolerance, mild gastritis	No	NS	Divorced parents
Holaday et al. ³⁰ , 1994	USA	Case report	1	M	15	EDNOS	CD	Delayed puberty	NS	Psychological and family therapy	Teased at school for short stature, sexually abused, unwed mother
Rickards et al. ³⁹ , 1994	UK	Case report	1	F	15	AN	CD	Cyclical neutropenia	NS	Admission to psychiatric unit, behavioural therapy	Divorced parents
Blanchet & Luton ¹⁹ , 2002	France	Case report	1	F	25	AN	CD		NS	Admission to psychiatric unit and psychotherapy	
Baylé & Bouvard ³¹ , 2003	France	Case report	1	F	16	AN	CD		Yes	Psychotherapy sessions	Teased at school for overweight
Evert et al. ³² , 2005	Germany	Case report	1	F	23	AN	CD	Pancreatic fibrosis and focal pancreatic atrophy	NS	No treatment due to death	
Culkin et al. ³³ , 2012	UK	Case report	1	F	36	BN ^a	CD	Obsessive Compulsive Disorder, Personality Disorder	NS	She discontinued psychotherapy sessions	Abused and neglected in childhood
Erdur et al. ²⁷ , 2012	Germany	Epidemiological cohort	1	F	-	AN	CD		NS	Individual and group therapy, art therapy, concentrative movement therapy and relaxation	
			1	F	-	AN	UC		NS		
			1	F	-	AN	CC		NS		
Solmi et al. ³⁴ , 2013	Italy		1	F	26	AN	CD		Yes	Psychodynamic therapy,	Criticized at a ballet audition

									dietary program, psycho- education	for the body shape
Wotton et al. ²⁸ , 2016	UK	Epidemio- logical cohort	83	F	-	AN	CD	NS	NS	
			62	F	-	AN	UC	NS	NS	
			32	F	-	BN	CD	NS	NS	
			22	F	-	BN	UC	NS	NS	
Our case	Spain		1	F	20	EDNOS	CD	Adjustment Disorder	Yes	Behavioural and dietary regime during admission in Gastroenterology Ward

AN = Anorexia Nervosa; BN = Bulimia Nervosa; CC = Collagenous Colitis; CD = Crohn's Disease; ED = Eating Disorder; EDNOS = Eating Disorder Not Otherwise Specified; F = female; IBD = Inflammatory Bowel Disease; M = male; NS = Not Specified; UC = Ulcerative Colitis;; ^a = those using the disease to lose weight

A total of 219 patients, including our case, with a comorbid diagnosis of IBD and ED have been reported in the scientific literature (Table II). The vast majority were females, with only three cases reported on males. The mean ages ranged from 10 to 44. AN (n=156) and CD (n=129) were the most prevalent diagnosis amongst ED and IBD respectively. In fact, the comorbidity between them, AN plus CD, has been the most frequent combination reported in the literature (n=90) (see figure 2 for more details). The index diagnosis was IBD in 106 out of 211 patients, while ED was the first diagnosis made in 105 out of 211 (See figure II). There were no data on first diagnosis in 8 patients. ED were clinically diagnosed in case reports and in the two epidemiological studies they did not report any screening instrument (the cohorts were from subjects with ED).

Figure II. Distribution of comorbid eating disorder by diagnosis of Inflammatory Bowel Disease published in the literature (number of cases)



Clinical presentations were reported for seventeen patients with IBD and ED comorbidity: weight loss (n=16), abdominal pain (n=12), diarrhoea (n=7), anaemia (n=6), amenorrhoea (n=6), self-induced vomiting (n=5), bloody diarrhoea (n=5), asthenia (n=3), anorexia (n=3), nausea (n=3), vomiting (n=3), failure to thrive (n=2), hypoproteinaemic or edema (n=2), constipation (n=2), cachexia (n=1), early satiety (n=1), dizziness (n=1), dyspnoea (n=1), syncope (n=1), dysphagia (n=1) and sore throat (n=1). The two retrospective cohort studies^{27,28} did not report any sign or symptom.

Of the seventeen patients described in case reports or case series studies, five of them used the IBD symptomatology to potentiate weight loss (it was suspected in another case but not confirmed) with methods specified in 4 cases: 1) by taking laxatives; 2) by taking products with lactose despite being intolerant to it; 3) by combining both previous methods; and 4) by using stoma as a purging device. Improvement is reported only in one case, where AN symptoms improved after TNF- α therapy prescribed for CD. In contrast, severe impairment and fatal outcomes were reported for most of the patients: five patients required bowel resections, two patients developed toxic megacolon and one died as a result of occult perforation of the colon and severe cachexia. In relation to the treatment, enteral nutrition (n=4) and parenteral nutrition (n=6) were in general well tolerated. Lack of adherence to prescribed treatment was described in 6 patients. And among the 10 patients receiving corticosteroid therapy, another six of them showed concern or refusal to being treated with corticoids in relation to weight gain.

DISCUSSION

The main findings of our systematized review focused on comorbidity between IBD and ED are: 1) CD and AN are the two comorbid disorders more frequently reported; 2) epidemiologically, comorbid IBD and ED is mostly reported in young women; and 3) IBD symptoms have been reported to be used for potentiating weight loss in some cases.

Several reported papers that mention IBD and ED are focused on the misdiagnosis between CD and AN¹⁴⁻²¹, being the differential diagnosis sometimes difficult to establish. The first case with a comorbid diagnosis of IBD and ED was reported by Sreenivasan³⁵ in 1984. Since then, other authors have reported cases with ED and IBD, and several studies screening ED in patients with IBD have been published^{24,25,27,40,41}, the most recent one²⁸ in 2016.

The scientific literature suggests that there is an association between ED and IBD, although more research is required to confirm this^{24,25,28}. The direction of the relationship between IBD and ED also remains unclear; it is not known whether IBD leads to the development of an ED, if it is the reverse, or if the relationship is bidirectional. Wotton et al.²⁸ observed a significant elevated risk of being diagnosed with Ulcerative Colitis (UC), five or more years after the first admission due to AN. They also reported on a higher risk of CD in patients diagnosed with AN,

and vice-versa, within the first year after an admission. Similar results were described in another study²⁵, where they found that the incidence and lifetime prevalence of CD were increased in patients with ED. Regardless of the direction of this link, comorbidity may lead to significant delays in diagnosis and complex therapeutic management^{19,27,29,30,32,39}. In our case, the patient showed abnormal eating behaviours since the age of 14, although the diagnosis of EDNOS was not made until she was 20. Although epidemiological studies did not report the age of the subjects, from the individual cases descriptions, it seems that this comorbidity should be especially considered in the differential diagnosis within younger patients. Additionally, the association between IBD and ED may also worsen the prognosis of both conditions⁴² and even threaten patient's life as some examples found in this review.

Several risk factors have been hypothesized to relate ED with a diagnosis of IBD: delayed growth and puberty onset, preoccupation with dietary management, fear of abdominal discomfort from eating food, weight and body shape concerns, poor body image, poor emotional well-being, disease severity, body shame (e.g. use of colostomy or ileostomy bag), impaired personal relationships and physical limitations⁴³. With regards to ethio-pathogenesis theories that relate both diseases, some explanations have been raised focusing primarily in three aspects: 1) role of diet; 2) changes in body shape because of drug therapy for IBD; 3) immune-inflammatory pathogenesis.

Regarding the role of diet in patients with IBD, Hughes et al.¹¹ has recently validated the Food-Related Quality of Life-29 questionnaire (FR-QoL-29). This questionnaire has been developed specifically for patients diagnosed with IBD to evaluate eating behaviours and dietary changes related with the disease and its consequences in terms of quality of life. Relative to this, some studies have suggested that these modifications in dietary patterns and gastrointestinal symptoms presented in patients with IBD may act as predisposing factors for ED^{13,24}. Some of these factors are:

- The subjective perception of patients of some aliments triggering their IBD symptoms although scientific evidence is not enough to support this relation¹¹.

- Dietary recommendations for IBD, which often include hyperphagic diets to compensate the malabsorption due to the disease and/or short bowel syndrome after massive bowel resections³³; in order to avoid malnutrition and/or delayed growth in youngsters⁴³.
- The need of enteral or parenteral nutrition, required for treatment in some cases, may complicate the reestablishment of food intake, as the case we presented and other one reported in the literature³¹.
- Additionally, exacerbations of postprandial abdominal pain, early satiety, anorexia or nausea have been described in patients with upper gastrointestinal CD and weight loss, which could be specially exacerbated due to the delayed gastric emptying of solids shown in AN and CD³⁸.

All this may lead to food avoidance behaviours, modifying normal eating habits and increasing weight loss^{13,37,39}.

In relation to secondary effects of treatment, Meadows and Treasure³⁶ were the first who proposed that changes in body shape due to corticotherapy, could explain a link between ED and IBD. The appearance of acne, moon face, oedema, and skin striae are frequent early adverse effects associated with a supra-physiological dose of corticosteroids, currently used to induce remission in CD⁴⁴. These changes may modify the body shape of the patient and increase their weight, resulting in triggering restrictive and/or purgative behaviours to regulate it. This theory has been supported by other authors who have described similar cases^{31,37,38} in which patients refused prescribed corticosteroids. This time sequence, however, is not applicable to the cases where ED is the initial diagnosis^{19,29,34,37-39}. Other drugs used for IBD treatment, as tacrolimus, have been reported to induce anorexia nervosa-like symptoms in children^{5,45}.

In recent years, Solmi et al.³⁴ have offered a novelty immuno-inflammatory hypothesis suggesting that proinflammatory cytokines (IL-6 and TNF- α), which levels are increased in CD, may be involved in the maintenance of AN symptoms. These substances and hypothalamic neuropeptides have common ways in regulating hunger/satiety and energy expenditure. Over-expression of the IL-6 may contribute to increase levels of anorexigenic peptides (pro-opiomelanocortin and corticotrophin-releasing hormone) and decrease orexigenic peptides

(neuropeptide Y, agouti-related, melanin-concentrating hormone, prepro-orexin)⁴⁶. Additionally, IL-6 facilitates satiety by stimulating leptin sensitivity at the hypothalamus. Likewise, TNF- α promotes the effect of anorexigenic peptides in inflammatory diseases as IBD³⁴. It has been also found increased levels of autoantibodies (autoAbs) against peptides related with appetite, body weight and suppression of food intake (α -melanocyte-stimulating hormone, oxytocin, vasopressin, luteinizing hormone-releasing hormone, adrenocorticotrophic hormone) in patients with ED as well as in control subjects⁴⁷. Although these autoAbs are not sufficient to cause ED⁴⁷, it has been suggested that non-harmful autoAbs may become pathogenic and contribute to the development of ED by different mechanisms^{47,48}: 1) autoAbs may cross the blood-brain barrier and disrupt signalling at the MC4 melanocortin receptor, related with weight regulation; 2) autoAbs may also interfere with signalling on the MC3 melanocortin receptor of the arcuate nucleus, located outside the blood-brain barrier and associated with the control of food intake by substances such as neuropeptide Y (NPY); 3) autoAbs may block α -MSH function and suppress the production of IL-1 and TNF- α , inhibiting food intake; and 4) autoAbs may occupy serotonin-binding sites and increase its concentration, which is a common feature found in plasma of AN patients. In this regard, several studies have described similar features for patients with IBD. It has been found that disruption in MC1 melanocortin receptor signalling may lead to worsening of colitis in mice⁴⁹. In fact, one study showed a reduction of intestinal inflammation in murine models being treated with melanocortin-derived tripeptide α -MSH (KPV)⁵⁰. Lower plasmatic levels of NPY have also been found in patients with IBD than in control subjects, suggesting a key role of NPY in the development of IBD by interacting with other substances as serotonin and somatostatin⁵¹. Likewise, serum serotonin levels may be associated and correlated with a higher pouch endoscopy inflammation in and cuffitis⁵².

Additionally, another study⁵³ showed lower levels of acyl ghrelin IgG autoAbs in patients with AN than in healthy subjects. In contrast, ghrelin reactive autoAbs bind mainly to des-acyl ghrelin in control subjects. In case of IBD patients, serum ghrelin levels seem to be higher in active disease than in IBD patients in remission. These elevated levels correlate with severity of the IBD and the activity markers⁵⁴. These features suggest a possible link between gut and brain. However, it remains unclear whether these substances play a role in the pathogenesis or maintenance of ED³⁴.

The main limitation of this review is inherent to the publication bias: there are few articles focused on this topic and they are mainly case series. Besides, it should be taken into account that frequently, published case reports are those with unusual presentations or outcomes due to their severity. At the same time, this could also support our view that less severe patients suffering this comorbidity could be underreported and/or underdiagnosed. It needs to be also highlighted that none of the publications included reported longitudinal prospective data and that only one author performed the article selection. Nevertheless, as a strength, to the authors' knowledge this is the first review addressing this comorbidity, exhaustively reviewing all published data and suggesting plausible etiopathogenic mechanisms underlying this association. Although literature is scarce and conclusions should be taken cautiously, it is a relevant topic in daily clinical practice and its interest is growing in latest years as reflected in recent epidemiological studies^{24,25,27,28}.

CONCLUSION

Recent evidence suggests a possible association between IBD and ED, and some theories and risk factors have been proposed in this regard. Nevertheless, the mechanisms involved in its etiopathogenesis are still unknown. To be aware of this condition is important because a delayed diagnosis of comorbid IBD and ED may lead to worse prognosis. Considering our experience in the management of the case described above and the cases reported by other authors, there are some clinical implications that could be of interest for clinicians. First, ED diagnosis should be considered in patients with IBD. Second, multidisciplinary approach would be recommended in these complex cases to provide an adequate therapeutic intervention. Third, screening tools to evaluate eating attitudes and behaviours in patients with IBD could be used in daily practice, as for example the Eating Attitude Test – 26^{11,55}. Further research, mostly prospective studies, is needed to firmly support this link, and to identify clinical and/or biological markers which could facilitate earlier diagnosis.

ACKNOWLEDGMENTS

We would like to thank Ellen Grimås for her contribution reviewing orthography and stylistic aspect of the writing.

FUNDING STATEMENT

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CONFLICTS OF INTEREST

M. Fabrega and D. Ilzarbe are grant-holders from Alicia Koplowitz Foundation. No other conflicts of interest.

ABBREVIATIONS

AN: Anorexia Nervosa

AutoAbs: Autoantibodies

BN: Bulimia Nervosa

CC: Collagenous Colitis

CD: Crohn's Disease

ED: Eating Disorders

EDNOS: Eating Disorder No Otherwise Specified

IBD: Inflammatory Bowel Disease

MOOSE: Meta-Analyses and Systematic Reviews of Observational Studies

UC: Ulcerative Colitis

REFERENCES

1. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. *Clin Epidemiol* 2013; 5: 237-247. doi: 10.2147/CLEP.S33961.
2. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; 142(1): 46-54. doi: 10.1053/j.gastro.2011.10.001.
3. Gomollón F, Sans M. Enfermedad Inflamatoria Intestinal. Enfermedad de Crohn. In: Montoro MA, García JC, editores. *Gastroenterología y hepatología. Problemas comunes en la práctica clínica*. 2ª ed. Madrid: Jarpyo; 2012. p. 443-458.
4. Deshmukh P, Kulkarni G, Lackamp J. Inflammatory Bowel Disease in children: psychological and psychiatric issues. *Curr Psychiatry Rep* 2010; 12(3): 222-228. doi: 10.1007/s11920-010-0111-0.
5. Larion S, DeCecchis DP, Arnold JM, Vanslyke JA, Tavakoli HR. Psychiatric comorbidities in Inflammatory Bowel Disease. *Curr Psychiatry Rev* 2015; 11(2): 124-129. doi: 10.2174/157340051102150502083333.
6. Neuendorf R, Harding A, Stello N, Hanes D, Wahbeh H. Depression and anxiety in patients with Inflammatory Bowel Disease: A systematic review. *J Psychosom Res* 2016; 87: 70-80. doi: 10.1016/j.jpsychores.2016.06.001.
7. Knoll S, Föcker M, Hebebrand J. Changes to the classification of Eating Disorders in DSM-5. *Z Kinder Jugendpsychiatr Psychother*. 2014; 42(5): 361-6. doi: 10.1024/1422-4917/a000311.
8. Smink FR, van Hoeken D, Hoek HW. Epidemiology of eating disorders: incidence, prevalence and mortality rates. *Curr Psychiatry Rep* 2012; 14(4): 406-414. doi: 10.1007/s11920-012-0282-y.
9. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*. Washington DC: American Psychiatric Association; 2013.
10. Miller C, Golden N. An introduction to eating disorders: clinical presentation, epidemiology, and prognosis. *Nutr Clin Pract* 2010; 25(2): 110-115. doi: 10.1177/0884533609357566.
11. Hughes LD, King L, Morgan M, Ayis S, Direkze N, Lomer MC, Lindsay JO, Whelan K. Food-related quality of life in inflammatory bowel disease: development and validation of a questionnaire. *J Crohns Colitis* 2016; 10(2): 194-201. doi: 10.1093/ecco-jcc/jjv192.

12. Norman K, Kirchner H, Lochs H, Pirlich M. Malnutrition affects quality of life in gastroenterology patients. *World J Gastroenterol*. 2006; 12(21): 3380-3385. doi: 10.3748/wjg.v12.i21.3385.
13. Satherley R, Howard R, Higgs S. Disordered eating practices in gastrointestinal disorders. *Appetite*. 2015; 84: 240-250. doi: 10.1016/j.appet.2014.10.006.
14. Gryboski JD, Katz J, Sangree MH, Herskovic T. Eleven adolescent girls with severe anorexia. Intestinal disease or anorexia nervosa? *Clin Pediatr (Phila.)* 1968; 7(11): 684-690.
15. Metcalfe-Gibson C. Anorexia nervosa and Crohn's disease. *Br J Surg* 1978; 65(4): 231-233.
16. Hershman MJ, Hershman M. Anorexia nervosa and Crohn's disease. *Br J Clin Pract* 1985; 39(4): 157-159.
17. Jenkins AP, Treasure J, Thompson RP. Crohn's disease presenting as anorexia nervosa. *Br Med J (Clin Res Ed)* 1988; 296(6623): 699-700.
18. Andant C, Godeberge B, Chaussade S, Dupas JL, Soulé JC. Aspects cliniques et évolutifs de la maladie de Crohn duodéno-jéjunale symptomatique. *Gastroenterol Clin Biol* 1999; 23: 1134-1138.
19. Blanchet C, Luton JP. Anorexie mentale et maladie de Crohn: intrications et difficultés diagnostiques. *Presse Med* 2002; 31(7): 312-315.
20. Markella M, Cerimele JM. Psychiatric presentation of a child with Crohn's disease. *Prim Care Companion J Clin Psychiatry* 2010; 12(5): e1. doi: 10.4088/PCC.10I00955blu.
21. Tylec A, Dubas-Ślęmp H, Perzyńska-Starkiewicz A, Olajossy M. The problem of anorexia nervosa diagnosis: a case study. *Acta Neuropsychol* 2014; 12(4): 493-501. doi: 10.5604/17307503.1138850.
22. Preti A, Girolamo Gd, Vilagut G, Alonso J, Graaf Rd, Bruffaerts R, Demyttenaere K, Pinto-Meza A, Haro JM, Morosini P. The epidemiology of eating disorders in six European countries: results of the ESEMeD-WMH project. *J Psychiatr Res* 2009; 43(14): 1125-1132. doi: 10.1016/j.jpsychires.2009.04.003.
23. Hoek HW, van Hoeken D. Review of the prevalence and incidence of eating disorders. *Int J Eat Disord* 2003; 34(4): 383-396. doi: 10.1002/eat.10222.
24. Quick VM, McWilliams R, Byrd-Bredbenner C. Case-control study of disturbed eating behaviours and related psychographic characteristics in young adults with and without diet-

- related chronic health conditions. *Eat Behav* 2012; 13(3): 207-213. doi: 10.1016/j.eatbeh.2012.02.003.
25. Raevuori A, Haukka J, Vaarala O, Suvisaari JM, Gissler M, Grainger M, Linna MS, Suokas JT. The increased risk for autoimmune diseases in patients with eating disorders. *PLoS One* 2014; 9(8): e104845. doi: 10.1371/journal.pone.0104845.
 26. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283:2008-12.
 27. Erdur L, Kallenbach-Dermutz B, Lehmann V, Zimmermann-Viehoff F, Köpp W, Weber C, Deter HC. Somatic comorbidity in anorexia nervosa: first results of a 21-year follow-up study on female inpatients. *Biopsychosoc Med* 2012; 6(1): 4. doi: 10.1186/1751-0759-6-4
 28. Wotton CJ, James A, Goldacre MJ. Coexistence of eating disorders and autoimmune disease: record linkage cohort study, UK. *Int J Eat Disord* 2016; 49(7): 663-672. doi: 10.1002/eat.22544.
 29. Anonymous. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-1985. *N Engl J Med* 1985; 312(18): 1175-83.
 30. Holaday M, Smith KE, Robertson S, Dallas J. An atypical eating disorder with Crohn's disease in a fifteen-year-old male: a case study. *Adolescence* 1994; 29(116): 865-873.
 31. Baylé FJ, Bouvard MP. Anorexia nervosa and Crohn's disease dual diagnosis: a case study. *Eur psychiatry* 2003; 18(8): 421-422.
 32. Evert M, Seiler C, Dombrowski F. Aberrant acinar cell CA19-9 expression and peri-insular acinar cell alterations in an adult human pancreas. *Virchows Arch* 2005; 446(1): 68-72. doi: 10.1007/s00428-004-1132-z.
 33. Culkin A, Gabe SM, Peake STC, Stern JM. A dangerous combination of binge and purge. *Int J Eat Disord* 2012; 45(2): 302-304. doi: 10.1002/eat.20912.
 34. Solmi M, Santonastaso P, Caccaro R, Favaro A. A case of anorexia nervosa with comorbid crohn's disease: beneficial effects of anti-TNF- α therapy? *Int J Eat Disord* 2013; 46(6): 639-641. doi: 10.1002/eat.22153.
 35. Sreenivasan U. Anorexia nervosa associated with energy-wasting disorders. *Can Med Assoc J* 1984; 130(1): 45-46

36. Meadows G, Treasure J. Bulimia nervosa and Crohn's disease: two case reports. *Acta Psychiatr Scand* 1989; 79(4): 413-414.
37. Mallett P, Murch S. Anorexia nervosa complicating inflammatory bowel disease. *Arch Dis Child* 1990; 65(3): 298-300.
38. Gryboski JD. Eating disorders in inflammatory bowel disease. *Am J Gastroenterol* 1993; 88(2): 293-296.
39. Rickards H, Prendergast M, Booth IW. Psychiatric presentation of Crohn's Disease. Diagnostic delay and increased morbidity. *Br J Psychiatry* 1994; 164(2): 256-261.
40. Guthrie EA, Creed FH, Whorwell PJ. Eating disorders in patients with the irritable bowel syndrome: a comparison with inflammatory bowel disease and peptic ulceration. *Eur J Gastroenterol Hepatol* 1990; 2(6): 471-473.
41. Della Valle N, Principi M, Ierardi E. Alimentary disorders in young females with irritable bowel syndrome or ulcerative procto-sigmoiditis: a preliminary report [letter]. *J Crohns Colitis* 2013; 7(3): e112-113. doi: 10.1016/j.crohns.2012.07.015.
42. Mascolo M, Geer B, Feuerstein J, Mehler PS. Gastrointestinal comorbidities which complicate the treatment of anorexia nervosa. *Eat Disord* 2017; 25(2): 122-133. doi: 10.1080/10640266.2016.1255108.
43. Quick VM, Byrd-Bredbenner C, Neumark-Sztainer D. Chronic illness and disordered eating: a discussion of the literature. *Adv Nutr* 2013; 4(3): 277-286. doi: 10.3945/an.112.003608.
44. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzeño F, Vavricka S, Gionchetti P, ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. *J Crohns Colitis* 2017;11(1): 3-25. doi: 10.1093/ecco-jcc/jjw168.
45. Kemper MJ, Spartà G, Laube GF, Miozzari M, Neuhaus TJ. Neuropsychologic side-effects of tacrolimus in pediatric renal transplantation. *Clin Transplant* 2003; 17(2): 130-134.

46. Señarís RM, Trujillo ML, Navia B, Comes G, Ferrer B, Giralto M, Hidalgo J. Interleukin-6 regulates the expression of hypothalamic neuropeptides involved in body weight in a gender-dependent way. *J Neuroendocrinol* 2011; 23(8): 675-686. doi: 10.1111/j.1365-2826.2011.02158.x.
47. Fetissov SO, Harro J, Jaanisk M, Järv A, Podar I, Allik I, Nilsson I, Sakthivel P, Lefvert AK, Hökfelt T. Autoantibodies against neuropeptides are associated with psychological traits in eating disorders. *Proc Natl Acad Sci U S A* 2005; 102(41): 14865-14870. doi: 10.1007/s00428-004-1132-z.
48. Fetissov SO, Hallman J, Orelund L, Af Klinteberg B, Grenbäck E, Hulting AL, Hökfelt T. Autoantibodies against alpha-MSH, ACTH, and LHRH in anorexia and bulimia nervosa patients. *Proc Natl Acad Sci U S A* 2002; 99(26): 17155-17160. doi: 10.1073/pnas.222658699.
49. Maaser C, Kannengiesser K, Specht C, Lügering A, Brozka T, Luger TA, Domschke W, Kucharzik T. Crucial role of the melanocortin receptor MC1R in experimental colitis. *Gut* 2006; 55(10): 1415-1422. doi: 10.1136/gut.2005.083634.
50. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. *Inflamm Bowel Dis* 2008; 14(3): 324-231. doi: 10.1002/ibd.20334.
51. El-Salhy M, Hausken T. The role of the neuropeptide Y (NPY) family in the pathophysiology of inflammatory bowel disease (IBD). *Neuropeptides* 2016; 55: 137-144. doi: 10.1016/j.npep.2015.09.005.
52. Wang Y, Gong H, Lopez R, Lian L, Kiran RP, Soffer EE, Shen B. Correlation between serum serotonin and endoscopy inflammation scores in patients with ileal pouches. *J Crohns Colitis* 2013; 7(4): e133-142. doi: 10.1016/j.crohns.2012.07.028.
53. Terashi M, Asakawa A, Harada T, Ushikai M, Coquerel Q, Sinno MH, Déchelotte P, Inui A, Fetissov SO. Ghrelin reactive autoantibodies in restrictive anorexia nervosa. *Nutrition* 2011; 27(4): 407-413. doi: 10.1016/j.nut.2011.01.002.
54. Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. *Dig Dis Sci* 2008; 53(8): 2215-2221. doi: 10.1007/s10620-007-0113-x.

55. Garner DM, Garfinkel PE. The Eating Attitudes Test: an index of the symptoms of anorexia nervosa. *Psychol Med.* 1979;9(2): 273-9.

HIGHLIGHTS

1. Symptomatology overlaps between inflammatory bowel disease and eating disorders
2. Comorbidity should be considered in the differential diagnosis
3. Crohn's Disease and Anorexia Nervosa is the most frequent reported comorbidity
4. A delayed diagnosis of this comorbidity may lead to poorer prognosis
5. A multidisciplinary approach would be necessary to manage these cases